Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital

[1] Poynard T(2003)Viral hepatitis C Lancet 362 2095-2100

[2] Yuen MF(2005)Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 558-567

[3] Ratziu V(2006)Viral hepatitis C in Hong Kong Intervirology 49 23-27

[4] Lai CL(2009)Public health impact of antiviral therapy for hepatitis C in the United States Hepatology 50 1750-1755

[5] Shepard CW(2008)Changing trends in hepatitis C-related mortality in the United States, 1995–2004 Hepatology 47 1128-1135

[6] Finelli L(2001)Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial Lancet 358 958-965

[7] Alter MJ(2002)Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975-982

[8] Leung N(2010)Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C J Viral Hepat 17 34-50

[9] Chu C(2009)Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients Hepatology 49 729-738

[10] Tam JS(2009)Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 1827-1838

[1] Poynard T(2003)Viral hepatitis C Lancet 362 2095-2100

[2] Yuen MF(2005)Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 558-567

[3] Ratziu V(2006)Viral hepatitis C in Hong Kong Intervirology 49 23-27

[4] Lai CL(2009)Public health impact of antiviral therapy for hepatitis C in the United States Hepatology 50 1750-1755

[5] Shepard CW(2008)Changing trends in hepatitis C-related mortality in the United States, 1995–2004 Hepatology 47 1128-1135

[6] Finelli L(2001)Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial Lancet 358 958-965

[7] Alter MJ(2002)Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975-982

[8] Leung N(2010)Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C J Viral Hepat 17 34-50

[9] Chu C(2009)Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients Hepatology 49 729-738

[10] Tam JS(2009)Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 1827-1838